Skip to main content

Advertisement

SpringerLink
Log in

Public biotech in 2015 – the numbers

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Last year witnessed the biotech sector's first retreat from a multi-year run of incredible performance on the public markets.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: NASDAQ biotech index over time.
Figure 2: Public biotech barometers.
Figure 3: Global biotech IPOs through the years.
Figure 4: Global biotech industry financing.

Author information

Authors and Affiliations

  1. Chris Morrison is a freelance writer based in Yardley, Pennsylvania, USA,

    Chris Morrison

  2. Riku Lahteenmaki is a freelance writer working in Turku, Finland.,

    Riku Lähteenmäki

Authors
  1. Chris Morrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riku Lähteenmäki
    View author publications

    You can also search for this author in PubMed Google Scholar

Supplementary information

Supplementary Information

Supplementary Table 1 (XLS 191 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morrison, C., Lähteenmäki, R. Public biotech in 2015 – the numbers. Nat Biotechnol 34, 709–715 (2016). https://doi.org/10.1038/nbt.3630

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3630

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation